OPKO Health, Inc. (NASDAQ:OPK) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC boosted its stake in shares of OPKO Health, Inc. (NASDAQ:OPK) by 19.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 244,294 shares of the biotechnology company’s stock after acquiring an additional 39,459 shares during the period. SG Americas Securities LLC’s holdings in OPKO Health were worth $369,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in OPK. Verition Fund Management LLC purchased a new stake in shares of OPKO Health during the second quarter worth about $36,000. River Wealth Advisors LLC purchased a new stake in OPKO Health during the 3rd quarter worth approximately $38,000. Guggenheim Capital LLC acquired a new position in shares of OPKO Health during the first quarter valued at approximately $38,000. Point72 Hong Kong Ltd purchased a new position in shares of OPKO Health in the first quarter valued at approximately $39,000. Finally, HRT Financial LP purchased a new position in shares of OPKO Health in the first quarter valued at approximately $39,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

OPK has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Wednesday, April 3rd. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Friday, March 1st. Piper Sandler reissued an “overweight” rating and issued a $5.00 price target on shares of OPKO Health in a research note on Monday, April 1st. Finally, Barrington Research reaffirmed an “outperform” rating and set a $1.50 price objective on shares of OPKO Health in a research note on Monday, April 1st.

OPKO Health Stock Down 0.7 %

Shares of OPK opened at $1.35 on Monday. OPKO Health, Inc. has a 52-week low of $0.85 and a 52-week high of $2.24. The company has a quick ratio of 1.22, a current ratio of 1.55 and a debt-to-equity ratio of 0.15. The stock has a fifty day simple moving average of $1.02 and a two-hundred day simple moving average of $1.25. The company has a market capitalization of $940.94 million, a PE ratio of -5.40 and a beta of 1.82.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The firm had revenue of $181.90 million during the quarter, compared to analyst estimates of $177.53 million. During the same quarter in the prior year, the firm posted ($0.11) earnings per share. OPKO Health’s quarterly revenue was down 1.9% on a year-over-year basis. As a group, equities analysts forecast that OPKO Health, Inc. will post -0.33 EPS for the current year.

Insider Activity

In other OPKO Health news, Director Richard M. Krasno bought 30,000 shares of the business’s stock in a transaction on Monday, January 29th. The stock was bought at an average price of $0.99 per share, with a total value of $29,700.00. Following the completion of the purchase, the director now directly owns 103,333 shares in the company, valued at $102,299.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Vice Chairman Jane Ph D. Hsiao purchased 150,000 shares of OPKO Health stock in a transaction dated Wednesday, January 17th. The shares were acquired at an average cost of $0.95 per share, with a total value of $142,500.00. Following the purchase, the insider now owns 27,999,880 shares of the company’s stock, valued at $26,599,886. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Richard M. Krasno acquired 30,000 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was bought at an average price of $0.99 per share, for a total transaction of $29,700.00. Following the completion of the acquisition, the director now owns 103,333 shares in the company, valued at approximately $102,299.67. The disclosure for this purchase can be found here. Insiders bought a total of 6,691,531 shares of company stock valued at $6,384,039 in the last 90 days. Company insiders own 47.26% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.